Phase I/Ib study of Ad-SGE-REIC-GH in patient with liver cancer.

Phase 1

Recruiting

• Conditions: iver cancer

• Registration Number: JPRN-UMIN000027770
• Lead Sponsor: Okayama University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-20
• Last Update Posted: 17 October 2023
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

Patient with active bacterial, fungal or viral infections. Hepatitis B or C is allowed Patient with brain metastasis Patient with other malignancies HIV-positive Patient with angina pectoris, congestive heart failure, or myocardial infarction less than 1 year previously Patient with psychiatric illness that would limit compliance with study requirements Pregnant women, women suspect she is pregnant, or lactating woman Patient have a history of allergic reactions against drugs used in this study Any experimental anti-cancer drug therapy within 4weeks prior to this study Any anti-cancer drug therapy within 4 weeks prior to this study Patient received topical therapy within 4 weeks prior to this study Patient on anticoagulation or antiplatelet therapy Poor glycemic control measured as HbA1C >8.0 Patient is on chronic systemic steroid therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessment of safety

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR) Disease Control Rate (DCR)